UCB, a global biopharmaceutical company, announces the signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). Cizutamig, Candid’s lead investigational asset, is positioned as a potential best in class BCMA TCE for autoimmune diseases. Under the terms of the agreement, UCB will pay US $2 billion upfront payments and up to US $200 million in potential future milestone payments.
Read the full article: UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline with Novel T-cell Engagers //
Source: https://www.businesswire.com/news/home/20260503595444/en/UCB-to-Acquire-Candid-Therapeutics-Building-Upon-Its-Existing-Immunology-Pipeline-With-Novel-T-cell-Engagers